Alberto Papi

48.7k total citations · 14 hit papers
501 papers, 22.7k citations indexed

About

Alberto Papi is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology. According to data from OpenAlex, Alberto Papi has authored 501 papers receiving a total of 22.7k indexed citations (citations by other indexed papers that have themselves been cited), including 340 papers in Pulmonary and Respiratory Medicine, 294 papers in Physiology and 69 papers in Immunology. Recurrent topics in Alberto Papi's work include Asthma and respiratory diseases (291 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (218 papers) and Respiratory and Cough-Related Research (125 papers). Alberto Papi is often cited by papers focused on Asthma and respiratory diseases (291 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (218 papers) and Respiratory and Cough-Related Research (125 papers). Alberto Papi collaborates with scholars based in Italy, United Kingdom and United States. Alberto Papi's co-authors include Leonardo M. Fabbri, Sebastian L. Johnston, Gaetano Caramori, Marco Contoli, Helen K. Reddel, Christopher E. Brightling, Søren Pedersen, Paolo Casolari, Dave Singh and Marina Saetta and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alberto Papi

464 papers receiving 22.2k citations

Hit Papers

Asthma 2006 2026 2012 2019 2017 2016 2006 2006 2020 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Asthma
    2017 1.2k citations Alberto Papi, Christopher E. Brightling et al. profile →
  2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
    2016 976 citations Pascal Chanez, Alberto Papi et al. profile →
  3. Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations
    2006 781 citations Alberto Papi, Cinzia Maria Bellettato et al. American Journal of Respiratory and Critical Care Medicine profile →
  4. Role of deficient type III interferon-λ production in asthma exacerbations
    2006 777 citations Marco Contoli, Simon Message et al. profile →
  5. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
    2020 463 citations Gerard J. Criner, Alberto Papi et al. American Journal of Respiratory and Critical Care Medicine profile →
  6. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
    2017 452 citations John R. Hurst, Gerard J. Criner et al. European Respiratory Journal profile →
  7. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
    2023 405 citations Alberto Papi et al. profile →
  8. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
    2018 398 citations Alberto Papi, Leonardo M. Fabbri et al. profile →
  9. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
    2019 266 citations Richard Beasley, Alberto Papi et al. profile →
  10. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
    2022 244 citations Bartolomé R. Celli, Leonardo M. Fabbri et al. American Journal of Respiratory and Critical Care Medicine profile →
  11. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact
    2021 158 citations Alberto Papi, Marco Contoli et al. profile →
  12. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
    2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
  13. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
    2025 22 citations Gerard J. Criner, Alberto Papi et al. profile →
  14. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
    2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alberto Papi 14.1k 12.5k 4.2k 3.4k 2.5k 501 22.7k
Leonardo M. Fabbri 27.9k 2.0× 19.0k 1.5× 3.4k 0.8× 3.6k 1.0× 3.1k 1.2× 487 39.5k
Guy Brusselle 12.5k 0.9× 12.1k 1.0× 4.3k 1.0× 1.5k 0.4× 1.8k 0.7× 445 22.8k
Robert F. Lemanske 10.8k 0.8× 14.8k 1.2× 3.7k 0.9× 3.8k 1.1× 2.6k 1.0× 209 20.6k
Christopher E. Brightling 17.3k 1.2× 21.1k 1.7× 7.0k 1.6× 1.2k 0.4× 3.1k 1.2× 496 29.1k
Edwin K. Silverman 19.2k 1.4× 9.8k 0.8× 2.0k 0.5× 1.6k 0.5× 2.2k 0.9× 484 27.3k
Claus Vogelmeier 18.9k 1.3× 9.8k 0.8× 1.8k 0.4× 2.1k 0.6× 1.6k 0.6× 515 26.2k
Sebastian L. Johnston 12.8k 0.9× 14.8k 1.2× 8.3k 2.0× 11.1k 3.2× 5.5k 2.2× 408 29.9k
Stanley J. Szefler 14.7k 1.0× 18.2k 1.5× 2.3k 0.6× 1.1k 0.3× 1.6k 0.7× 487 23.9k
Romain Pauwels 18.3k 1.3× 17.6k 1.4× 3.2k 0.8× 1.2k 0.4× 1.7k 0.7× 146 26.3k
Peter Wark 4.6k 0.3× 4.9k 0.4× 3.1k 0.7× 2.4k 0.7× 1.3k 0.5× 247 10.9k

Countries citing papers authored by Alberto Papi

Since Specialization
Citations

This map shows the geographic impact of Alberto Papi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Papi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Papi more than expected).

Fields of papers citing papers by Alberto Papi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Papi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Papi. The network helps show where Alberto Papi may publish in the future.

Co-authorship network of co-authors of Alberto Papi

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Papi. A scholar is included among the top collaborators of Alberto Papi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Papi. Alberto Papi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Celli, Bartolomé R., Leonardo M. Fabbri, Gerard J. Criner, et al.. (2025). The ROME COPD exacerbation proposal works! Time to move forward. American Journal of Respiratory and Critical Care Medicine. 212(2). 294–296.
2.
Porsbjerg, Celeste, Eleanor M. Dunican, Njira Lugogo, et al.. (2025). Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. American Journal of Respiratory and Critical Care Medicine. 212(2). 241–252.
3.
Christenson, Stephanie A., Nicola A. Hanania, Surya P. Bhatt, et al.. (2025). Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 687–697. 5 indexed citations
4.
Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2025). Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. CHEST Journal. 168(1). 56–66. 1 indexed citations
5.
Papi, Alberto, Richard Beasley, Elliot Israel, et al.. (2024). Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation. The Journal of Allergy and Clinical Immunology In Practice. 12(10). 2847–2851.
6.
Tse, Gary, Benjamin Emmanuel, Cono Ariti, et al.. (2023). A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD. International Journal of COPD. Volume 18. 2565–2580. 12 indexed citations
7.
Price, David, William Henley, José Eduardo Delfini Cançado, et al.. (2022). Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. SHILAP Revista de lepidopterología. 6 indexed citations
8.
Canonica, Giorgio Walter, Pierluigi Paggiaro, Francesco Blasi, et al.. (2021). Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies. Therapeutic Advances in Respiratory Disease. 15. 2663621862–2663621862. 10 indexed citations
9.
Celli, Bartolomé R., Leonardo M. Fabbri, Shawn D. Aaron, et al.. (2021). An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. UCL Discovery (University College London). 94 indexed citations
10.
11.
Singh, Dave, Stefano Vezzoli, Stefano Petruzzelli, & Alberto Papi. (2017). The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study. International Journal of COPD. Volume 12. 3263–3271. 3 indexed citations
12.
Contoli, Marco, Kazuhiro Ito, Anna Padovani, et al.. (2015). Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 70(8). 910–920. 129 indexed citations
13.
Papi, Alberto, Pascal Chanez, Maciej Kupczyk, et al.. (2014). Frequent exacerbators - a distinct phenotype of severe asthma. Homo Politicus (Academy of Humanities and Economics in Lodz). 116 indexed citations
14.
Papi, Alberto, et al.. (2014). The awareness and use of electronic information resources by physicians in educational hospitals. SHILAP Revista de lepidopterología. 1 indexed citations
15.
Papi, Alberto, David Price, J. Sastre, et al.. (2013). Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone. European Respiratory Journal. 42(Suppl 57). P704–P704. 2 indexed citations
16.
Papi, Alberto, Marco Contoli, Ian M. Adcock, et al.. (2013). Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation. Journal of Allergy and Clinical Immunology. 132(5). 1075–1085.e6. 73 indexed citations
17.
Caramori, Gaetano, et al.. (2012). Ruolo delle cellule staminali nella patogenesi della broncopneumopatia cronica ostruttiva e dell’enfisema polmonare. Recenti Progressi in Medicina. 103(1). 31–40. 10 indexed citations
18.
19.
20.
Message, Simon, Vasile Laza‐Stanca, Patrick Mallia, et al.. (2008). Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proceedings of the National Academy of Sciences. 105(36). 13562–13567. 373 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonardo M. Fabbri Breakdown of academic impact, for papers by Guy Brusselle Breakdown of academic impact, for papers by Robert F. Lemanske Breakdown of academic impact, for papers by Christopher E. Brightling Breakdown of academic impact, for papers by Edwin K. Silverman Breakdown of academic impact, for papers by Claus Vogelmeier Breakdown of academic impact, for papers by Sebastian L. Johnston Breakdown of academic impact, for papers by Stanley J. Szefler Breakdown of academic impact, for papers by Romain Pauwels Breakdown of academic impact, for papers by Peter Wark
Rankless by CCL
2026